Founded in 2017, Bionaut Labs arrived out of stealth in March 2021, with plans to commercialize longstanding research around drug delivery robots. The Los Angeles-based startup today followed up its initial $20 million funding announcement with a $43.2 million Series B, bringing its total raised up to — you guessed it — $63.2 million. This round was led by Khosla Ventures and featured new investors Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, what if ventures, Tintah Grace and Gaingels.
If you’ve followed the robots space, you’re likely familiar with the research that has gone into these tiny, remote-controlled medical robots. Bionaut’s own work now has a couple of deadlines in place, including 2023 pre-clinical studies, followed by clinical trials with human patients the follow years.
“There has been a dearth of innovation around treatments for conditions that cause tremendous suffering, in …
